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Abstract The CCN family of proteins is composed of six
secreted proteins(CCN1-6), which aregrouped together based
on their structural similarity. These matricellular proteins are
involved in a large spectrum of biological processes, ranging
from development to disease. In this review, we focus on
CCN3, a founding member of this family, and its role in
regulating cells within the bone microenvironment. CCN3
impairs normal osteoblast differentiation through multiple
mechanisms, which include the neutralization of pro-
osteoblastogenic stimuli such as BMP and Wnt family signals
or the activation of pathways that suppress osteoblastogenesis,
such as Notch. In contrast, CCN3 is known to promote chon-
drocyte differentiation. Given these functions, it is not surpris-
ing that CCN3 has been implicated in the progression of
primary bone cancers such as osteosarcoma, Ewing’ss a r c o m a
and chondrosarcoma. More recently, emerging evidence sug-
gests that CCN3 may also influence the ability of metastatic
cancers to colonize and grow in bone.
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Abbreviations
ALP Alkaline phosphatase
BMP Bone morphogenetic protein
CT Carboxy-terminal region
ER Estrogen receptor
HSPG Heparan sulfate proteoglycans
IGF Insulin-like growth factor
IGFBP Insulin-like growth factor binding protein
ILK Integrin-linked kinase
JNK c-Jun kinase
LRP Low-density lipoprotein receptor-related protein
MAV Myeloblastosis-associated virus
M-CSF Macrophage colony stimulating factor
MMP Matrix metalloprotease
NFATc1 Nuclear factor of activated T cells c1
OPG Osteoprotegerin
RANKL Receptor activator of NF-κB ligand
TGF-β Transforming growth factor beta
TSG Twisted gastrulation
TSP-1 Thrombospondin-1
VEGF Vascular endothelial growth factor
VWC von Willebrand factor type C domain
WISP Wint-1 inducible signaling pathway protein
The CCN family of proteins
The CCN family of proteins emerged as an integrated entity in
2003, when a unified nomenclature was adopted by the scien-
tific community to reduce growing confusion in the literature
(Brigstock et al. 2003). The first letter from the three founding
members, which include Cyr 61 (cysteine rich 61), CTGF
(connective tissue growth factor) and Nov (nephroblastoma
overexpressed), was used to create the acronym CCN
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DOI 10.1007/s12079-012-0161-7(Perbal and Takigawa 2005). These three proteins became
known as CCN1, CCN2 and CCN3, respectively, and three
additional members were also identified at that time, in-
cluding CCN4 (WISP-1), CCN5 (WISP-2) and CCN6
(WISP-3). Based on a similar domain structure, these six
members have been grouped into the CCN family of
matricellular proteins.
CCN3, the nephroblastoma overexpressed gene
As its original name suggests, CCN3 was first discovered as a
gene that was overexpressed in a myeloblastosis-associated
virus (MAV-1)-induced nephroblastoma that developed in
chicken (Joliot et al. 1992). CCN3 is a cysteine-rich secretory
protein that associates with components of the extracellular
matrix. Since the discovery of this matricellular protein,
CCN3has beenimplicated in anincreasingnumber ofdiverse
biological processes including proliferation, differentiation
and angiogenesis as well as pathological conditions such as
fibrosis and cancer (Perbal 2001;B r i g s t o c k2003; Leask and
Abraham 2006;P e r b a l2006; Chen and Lau 2009;M c C a l l u m
and Irvine 2009; Zuo et al. 2010; Kular et al. 2011). This
diversity of CCN3 function is not surprising given the mod-
ular nature of CCN family members, which contains four
distinct domains that enable binding to numerous protein
partners. Layered on top of this large protein interaction
network, is the growing appreciation for the importance of
differential splicing and post-translational modifications, such
as glycosylation and proteolytic cleavage, which can greatly
influence CCN3 activity. Emerging evidence positions CCN3
as an important modulator of cancer progression and metas-
tasis. Thus, we will focus this review specifically on these
aspects of CCN3 biology as they relate to normal bone turn-
over, the growth of primary bone tumors and cancers that
metastasize to bone.
The modular structure of CCN3
With one exception, all CCN family members possess an
N-terminal signal peptide (SP) followed by four modular
domains with homology to an insulin-like growth factor bind-
ing protein (IGFBP) domain, a von Willebrand factor type C
domain (VWC), a Thrombospondin-1 type repeat (TSP-1)
and a C-terminal region (CT) containing a cysteine knot
structure. CCN5 is the only family member that deviates from
this overall domain organization due to the absence of the CT
domain (Pennica et al. 1998; Zhang et al. 1998). In each case,
the VWC and TSP-1 domains are separated by a variable
hinge region (Fig. 1).
IGFBP domain Theimportanceofthismoduleasafunctional
Insulin-like Growth Factors (IGF) binding domain in CCN
proteins, and itsbiologicalsignificance, remains unclear.Three
independentinvestigationshaveshownthatCCN3proteinlack
or exhibit very low binding affinities for IGF (Kim et al. 1997;
Burren et al. 1999; Vorwerk et al. 2002). The core members of
the IGFBP family contain both an N- and C-terminal IGF
binding domain, which act in concert to promote high affinity
ligand binding (Payet et al. 2003). In contrast, CCN proteins
possessa single N-terminalIGFBP domain. Thus, the 100-fold
reduction in IGF binding exhibited by CCN proteins, relative
to IGFBPs, was postulated to be due to the lack of this
C-terminal IGF binding domain. However, a chimeric protein
created by substituting the N-terminal IGFBP domain of
IGFBP-3 with the N-terminal IGFBP domain of CCN3 dis-
played very weak binding to IGFs similar to that observed for
CCN3.These data arguethattheCCN3 IGFBP domain is non-
functional for binding IGFs, even in the context of an N- and
C-terminal IGFBP domain configuration (Yan et al. 2006).
VWC domain This domain, also known as chordin-like
cysteine rich repeat, is commonly found in extracellular
matrix proteins. The VWC module was shown to be impor-
tant for the ability of CCN family members to bind Bone
Morphogenetic Protein (BMP) and Transforming Growth
Factor beta (TGF-β) (Abreu et al. 2002). In addition, it has
been suggested that this domain plays a role in oligomeri-
zation with members of the CCN family and a diverse array
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Fig. 1 Schematic diagram depicting the modular domains of CCN3.
CCN3 shares a similar overall structural organization with the remain-
ing CCN family members, including a secretory signal peptide (SP), an
insulin-like growth factor binding protein domain (IGFBP), a von
Willebrand factor type C domain (VWC), a Thrombospondin-1 type
repeat (TSP-1) and a carboxyl-terminal domain (CT) that contains a
cysteine knot. Known binding proteins are listed in black underneath
the particular domain through which they interact with CCN3. Proteins
denoted in grey are those for which the precise CCN3 domain respon-
sible for the interaction remains unknown, but has been defined in
other CCN family members. IGFs: Insulin-like Growth Factors, BMP:
Bone Morphogenetic Protein; Rbp7: Retinol Binding Protein 7; HSPG:
Heparan Sulfate Proteoglycan
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Perbal 2001).
Hinge region This region connects the VWC domain to
the TSP-1 like domain and is believed to be highly
susceptible to proteolytic processing. It was recently
shown that Kallikrein related peptidase 12 preferentially
cleaved CCN1 within the hinge region, although this
protease, when incubated in vitro with different recombi-
nant CCN proteins, including CCN3 displayed multiple
target sites for cleavage (Guillon-Munos et al. 2011).
Additional proteins, including Elastase, Plasmin and Ma-
trix Metalloproteases (MMP-1, MMP-2, MMP-3, MMP-
7, MMP-9 and MMP-13), have all been described to
cleave CCN family proteins in vitro (Brigstock et al.
1997; Hashimoto et al. 2002; de Winter et al. 2008).
While the relationship between processing events that
have been described in vitro to those that occur naturally
need to be further clarified, these cleaved CCN variants
and/or their ratio to the full length protein are thought to
significantly impact the functions of CCN family
members.
TSP-1 domain This domain is commonly found in a variety
of extracellular matrix proteins. Within the CCN family, this
region functions as a protein interaction domain that facili-
tates binding to Vascular Endothelial Growth Factor
(VEGF) (Inoki et al. 2002), integrin receptors and Low-
density Related Lipoprotein (LRP) (Gao and Brigstock
2003). These various interactions have been shown to be
important for the ability of CCN family members to control
tumor angiogenesis and breast cancer cell adhesion (Ellis et
al. 2003; Gao and Brigstock 2003; Lin et al. 2005; Tong and
Brigstock 2006)(reviewed in (Holbourn et al. 2009)).
CT domain The C-terminal module was named based on the
presence of a cysteine knot structure and is known to bind a
variety of proteins such as platelet-derived growth factor,
nerve growth factor, TGF-β, Heparin, Heparan Sulfate Pro-
teoglycans (HSPGs), Notch1 and Fibulin-1C (Brigstock et al.
1997; Kireeva et al. 1997; Chevalier et al. 1998;P e r b a le ta l .
1999; Sakamoto et al. 2002;B a l le ta l .2003). In addition, this
module promotes homo- or heterodimerization of CCN pro-
teins (Perbal et al. 1999; Lazar et al. 2007). The CT domain
also contains a nuclear localization signal, which has been
implicated in promoting interactions between CCN proteins
with transcription regulatory proteins (Mahony et al. 1999;
Perbal 1999; Planqueetal. 2006).The functionalimplications
of nuclear functions are not yet fully elucidated.
Thus,itisclear thatthemodulardomainstructureofCCN3
permits diverse protein interactions withmembers ofthe CCN
family, which may explain why these proteins elicit different
cellular responses depending on the cellular context.
CCN3 isoforms
The complexity surrounding CCN3 is, in part, related to the
different alternative splice variants and post-translational
modifications that alter CCN3 biological function (Perbal
2009). Several variants of CCN3 have been described in the
literature; however, their origins are not well described.
Thus, it is a challenge to determine whether these variants
result from alternate splicing or proteolytic cleavage or other
post-translational modifications. The human CCN3 is com-
posed of 357 amino acids with a predicted size of 44 kDa. It
possesses two putative N-glycosylation sites, one at position
97 (NQTG) and the second at 280 (NCTS), which results in
a secreted CCN3 protein with an apparent molecular weight
of 54 kDa (Chevalier et al. 1998). Thus, higher molecular
weight CCN3 isoforms result from post-translational glyco-
sylation and the lower molecular weight species are likely
derived from alternative splicing or proteolytic cleavage.
The first CCN3 variant to be described was an amino-
terminal truncation that resulted from integration of the
MAV virus, which removed the signal peptide and the
IGFBP domain, leaving only the lasts three modules
(VWC, TSP-1 and CT) (Joliot et al. 1992). This CCN3
variant was expressed in chicken embryo fibroblasts and
exhibited transforming properties. While it is unclear wheth-
er this isoform occurs naturally, it represents the first evi-
dence of a truncated form of CCN3 that retains biological
activity.
Alternative splicing Different studies have reported CCN3
variants that most likely arise from alternative splicing
(reviewed in (Perbal 2009)). Although consensus sequences
defining alternative splice sites have yet to be described for
CCN3, they have been identified in CCN1 (Martinerie et al.
1997; Leng et al. 2002; Hirschfeld et al. 2009) and CCN4
(Tanaka et al. 2001, 2003; Cervello et al. 2004; Yanagita et
al. 2007). However, the use of domain specific antibodies
has facilitated the identification of two CCN3 isoforms. One
lacks the TSP-1 domain and was reported to be localized in
the nucleus of kidney cancers (Subramaniam et al. 2008).
The other isoform of CCN3, devoid of the VWC module,
was detected in Ewing sarcoma cancer cells as well as in
developing mouse tissues (Heath et al. 2008; Perbal et al.
2009). While the presence of these CCN3 isoforms is in-
triguing, their precise biological roles have yet to be
elucidated.
Proteolytic processing Numerous publications have
reported proteolytically cleaved forms of CCN3 (reviewed
in (Perbal 2001)). However, only one group has investigated
the specific nature of the cleavage event. Following CCN3
overexpression in Sf9 insect cells, a secreted protein of
44 kDa was identified that was compatible with full-length
CCN3 in normal bone and cancer 75CCN3. In addition, a shorter 25 kDa form was found in the
insect cell conditioned media and was found to correspond
to the TSP-1 and CT domain (Perbal et al. 1999). N-terminal
microsequencing revealed that this CCN3 isoform resulted
from a cleavage event at amino acid 187, which is located
within the hinge region of CCN3. A truncated protein
corresponding to this size was also reported in canine
MDCK cells, HeLa human cervical cancer cells and BTK-
143 human osteosarcoma cells (Perbal 1999).
Several investigators have detected the presence of a
protein doublet migrating at 30 and 32 kDa in various
embryonic and adult tissues as well as several cancers.
Amino-truncated CCN3 variants of this size were reported
in diverse biological fluids, conditioned media, cytoplasm
and nucleus of several cell types [for example (Chevalier et
al. 1998; Burren et al. 1999; Perbal 1999; Ellis et al. 2000;
Su et al. 2001; Thomopoulos et al. 2001; Fu et al. 2004;
Kyurkchiev et al. 2004; McCallum et al. 2006; Vallacchi
and Rodolfo 2009)]. Finally, in brain and adrenal tissues
from the adult rat, isoforms of 38–40 kDa and 18 kDa were
observed and correspond to N-terminally truncated proteins.
It was proposed that these isoforms are derived from prote-
olysis and/or glycosylation of the CCN3 protein (Su et al.
2001).
It is clear that multiple isoforms of CCN3 exist, which
arise through alternative splicing or proteolytic processing.
It is less clear what effect these alternative CCN3 forms
have on biological responses to CCN3. Thus, it is conceiv-
able that the relative abundance of full length CCN3 to
variant CCN3 will dramatically influence how cells respond
to this protein and this underexplored aspect of CCN3
biology may account for some apparent discrepancies in
CCN3 action in various cell types.
CCN3 functions in normal bone physiology
Of the cell types that reside in the bone microenvironment,
osteoblasts are the bone forming cells and osteoclasts are
responsible for resorbing bone. Mesenchymal stem cells
differentiate into osteoblasts through a multi-step process
(Fig. 2a) that is stimulated by BMP and Wnt family mem-
bers and inhibited via Notch1 signaling (reviewed in
(Krishnan et al. 2006; Canalis 2008;L o n g2011)). The
proper differentiation of precursors into osteoblasts requires
expression of the Runx2 transcription factor, which acts as a
master regulator of this process (Marie 2008).
Following stimulation with factors such as Macrophage
Colony Stimulating Factor (M-CSF) and Receptor Activator
of NF-kB Ligand (RANKL), hematopoietic precursors dif-
ferentiate into mature activated osteoclast (Boyle et al.
2003). This process can be impaired by Osteoprotegerin
(OPG), a soluble decoy receptor for RANKL. The tight
control of the ratio between RANKL and OPG is critical
for maintaining homeostasis of the bone (Khosla 2001;
Dougall and Chaisson 2006; Ooi et al. 2011). The highest
level of RANKL is secreted from osteoblast precursors and
its expression decreases during osteoblast differentiation
whereas OPG levels are low in osteoprogenitors and in-
crease during osteoblastogenesis (Gori et al. 2000). In addi-
tion to RANKL and OPG, calcium signaling is critical for
osteoclast differentiation, in part through its ability to induce
nuclear localization of Nuclear Factor of Activated T cells
c1 (NFATc1), an important transcription factor for osteo-
clastogenesis (Negishi-Koga and Takayanagi 2009).
Several members of the CCN family have been shown to
regulate the differentiation of bone cells (Schutze et al.
2005;K a w a k ie ta l .2008;S ue ta l .2010) (reviewed in
(Yamaguchi et al. 2008; Katsube et al. 2009b; Arnott et al.
2011)). Indeed, CCN proteins are related to known antago-
nists of BMP proteins, such as Twisted Gastrulation (Tsg)
and Chordin (Garcia Abreu et al. 2002). Until recently, a
role for CCN3 in regulating the differentiation and function
of bone resident cells was not known. However, the activity
of CCN1 and CCN2 in these processes, coupled with the
identification of certain CCN3 interacting proteins such as
BMP and Notch, raised the possibility that CCN3 may also
regulate bone homeostasis.
To determine whether CCN3 also plays important roles in
the bone, mice overexpressing CCN3 in osteoblasts, under
control of the osteocalcin promoter, were generated and char-
acterized (Rydziel et al. 2007). Two independent transgenic
lines were analyzed; the first exhibiting CCN3 expression in
calvarial extracts that ranged between 25 and 250 times the
levels detected in non-transgenic controls. Male and female
mice, which were heterozygous for the transgene, displayed a
30–35% decrease in trabecular bone volume but exhibited
similarnumbersofosteoblasts,osteoclastsandsimilardegrees
of bone erosion. However, diminished mineral apposition and
bone formation was observed, which suggested impaired os-
teoblastfunction. Inthe secondtransgenicline, CCN3mRNA
expression ranged from 1,000 to 9,000-fold higher when
compared to the wild type control mice. Animals from this
transgenic line suffered from osteopenia, a condition charac-
terized by significantly diminished bone mineral density. This
phenotype was correlated with an increase in bone resorption
and elevated osteoclast numbers along the eroded bone surfa-
ces. These data argue that CCN3 plays a significant role in
suppressing osteoblast differentiation and, at high concentra-
tions, may enhance osteoclast differentiation or function.
This conclusion was further supported by phenotypes
associated with mice bearing a targeted disruption in the
CCN3 gene. These mice were engineered to express a
CCN3del3 mutant, which encoded a protein lacking the
VWC domain (Heath et al. 2008). While full length CCN3
could not be detected in these animals, the CCN3del3
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ly, a transcript lacking the VWC domain was also present in
several tissues of the wild-type embryos, raising the possi-
bility that this isoform of CCN3 could arise naturally from
alternative splicing. In CCN3del3 expressing embryos, the
skeleton showed abnormalities such as enlarged vertebrae,
elongated long bones and digits. In addition, joint defects
such as fusions, malformations, dislocations and laxity were
observed mice expressing CCN3del3. In adult animals,
overgrowth of the bone and joint defects were also reported.
These data argue that the normal role for CCN3 is to
suppress bone formation by osteoblasts, and that the loss
of CCN3 resulted in excessive bone formation. However,
the authors could not definitively conclude that skeletal
phenotypes observed in the CCN3del3 mice resulted from
the loss of CCN3 or to a new function ascribed to the
truncated CCN3del3 protein (Heath et al. 2008).
More recently, a complete knock-out of CCN3, in which
exons 1, 2 and a portion of exon 3 were removed, has been
described (Shimoyama et al. 2010). No overt skeletal phe-
notypes were reported in these CCN3
−/− mice; however, this
study focused primarily on the role of CCN3 in the vascu-
lature (Shimoyama et al. 2010). Another CCN3 null mouse
has been developed, where the entire coding sequence of
CCN3 was deleted (Canalis et al. 2010). CCN3 null mice
did not demonstrate skeletal abnormalities during develop-
ment and only very modest bone defects were observed with
low penetrance. For example, an increase in osteoblast
numbers/bone surface, mineralization and bone formation
was apparent in ten-month-old females; however, this phe-
notype was not evident in males of the same age (Canalis et
al. 2010).
Another interesting aspect of CCN action within the bone
microenvironment is their potential roles in the fracture
repair process. Indeed, CCN1, CCN2 and CCN4 have all
been shown to be overexpressed during various phases of
the fracture repair process (Hadjiargyrou et al. 2002; Nakata
et al. 2002; French et al. 2004). Moreover, blocking anti-
bodies against CCN1 disrupt fracture healing, providing
evidence that CCN family members play a functional role
in this process (Athanasopoulos et al. 2007). To date, no
studies have implicated CCN3 in fracture repair and
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Fig. 2 CCN3 is a physiological regulator of osteoblast differentiation.
a Schematic depicting the different stages during osteoblast differenti-
ation. The prevailing data suggests that CCN3 can block the differen-
tiation of mesenchymal stem cells and/or osteoprogenitors into
committed pre-osteoblasts. As mesenchymal stem cells differentiate
into mature osteoblasts, Receptor Activator of NF-κBL i g a n d
(RANKL) expression decreases and the levels of Osteoprotegerin
(OPG), a decoy receptor for RANKL, increase. Thus, CCN3 would
have the indirect effect of elevating the RANKL/OPG ratio in pre-
osteoblasts by impairing osteoblast differentiation. b Mechanisms un-
derlying CCN3-mediated blockade of osteoblast differentiation. CCN3
can directly bind and neutralize BMP-2, a potent osteoblastic factor. In
addition, CCN3 can indirectly inhibit BMP2 effect by increasing the
level of Gremlin, a known antagonist of BMP2, by favoring the
stabilization of Gremlin mRNA. CCN3 also counteracts the signaling
of Wnt3, by causing a reduction of β-Catenin levels and a subsequent
diminishment of Wnt3 target genes, through a mechanism that does not
interfere with the ligand-receptor interaction. CCN3 can also bind and
activate Notch, causing the release the Notch intracellular domain
(NICD). The NICD induces the expression of Hairy/Enhancer of Split
(HES) and Hairy/Enhancer of Split with YRPW motif 1 (HEY), which
in turn physically interact with and repress Runx2 activity, a key
transcription factor involved in osteoblast differentiation
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further clarify the influence of CCN3 on bone resident cells.
Taken together, these data argue that CCN3 can influence
osteoblast, and potentially osteoclast, differentiation and/or
function. However, it is clear that CCN3 exerts the greatest
effects on bone formation/remodeling when it is overex-
pressed, rather than when physiological levels of CCN3
are lost. Another important aspect when evaluating the role
of CCN3 in bone is the expression level of the other CCN
family members, including CCN1 and CCN2. For example,
studies on CCN2
−/− mice revealed that CCN3 becomes
overexpressed in a context of CCN2 knock-out (Kawaki et
al. 2008). Considerations such as these may be important in
understanding CCN3 action in bone and begin to shed light
on factors that may influence the cellular context in which
CCN3 can exert its biological effects.
Mechanisms of CCN3 action in osteoblasts
The above studies argue that CCN3 regulates osteoblast
differentiation. While several of these in vivo studies suggest
that CCN3 can negatively regulate osteoblast differentia-
tion, the mechanisms underlying CCN3 action have been
revealed using in vitro cell culture systems. Using a MC3T3
murine calvarial derived cell model, which can be induced
to differentiate into osteoblast-like cells, CCN3 was shown
to inhibit osteoblast differentiation by binding to and neu-
tralizing BMP2, a well-known enhancer of osteoblastogen-
esis (Minamizato et al. 2007). This led to diminished mRNA
expression of several BMP2 target genes, such as Runx2,
Osterix, Alkaline Phosphatase (ALP) and Osteocalcin. In
addition, CCN3 was also shown to augment the release of
the Notch Intracellular Domain (NICD) from full length
Notch, leading to an increase in Hairy/Enhancer of Split
(HES) and Hairy/Enhancer of Split with YRPW motif 1
(HEY) transcription and ultimately to impaired osteoblast
differentiation (Minamizato et al. 2007).
In another study, CCN3 overexpression in ST-2 cells, a
stromal cell line derived from mouse bone marrow, also
resulted in a block in osteoblast differentiation (Rydziel et
al. 2007). CCN3-expressing ST-2 cells displayed reduced
numbers of mineralized nodules and diminished levels of
Smad-1, Smad-5, and Smad-8 phosphorylation when these
cells were stimulated with BMP2. In this cell system, CCN3
exerted these effects by directly binding and neutralizing
BMP2 and through impairment of Wnt3 signaling (Rydziel
et al. 2007). Likewise, using ST-2 and MC-3T3 cells, CCN3
was shown to impair osteoblast differentiation through
BMP2 neutralization and impairment of Wnt3 signaling, in
a Notch independent manner (Canalis 2007).
Yet another potential mechanism has been proposed to
account for CCN3-mediated impairment of osteoblast
differentiation. Overexpression of CCN3 in ST-2 cells leads
to increased Gremlin expression, a known BMP2 antagonist
(Gazzerro and Canalis 2006), through a mechanism involv-
ing Gremlin mRNA stabilization (Smerdel-Ramoya et al.
2011). Thus, CCN3 can function to blunt BMP2 action by
directly binding and neutralizing BMP2 or through indirect
mechanisms that involve stabilization of BMP2 antagonists.
CCN3 was shown to decrease proliferation and osteoblast
differentiation of Kusa-A1osteogenicmesenchymalstemcells
through Notch-1 mediated p21 upregulation. This inhibitory
functionwasalsodependentonCCN3’s ability to bind directly
to BMP2. These results argued that the ability ofCCN3 to bind
BMP2 in a CT domain independent manner is an important
mechanism through which it can block osteoblast differentia-
tion (Katsuki et al. 2008; Katsube et al. 2009a).
These findings are supported by the observation that
primary calvarial bone marrow cells from CCN3
−/− mice
revealed enhanced osteoblast differentiation in response to
BMP2 when compared to cultures from wild-type controls
(Canalis et al. 2010). Moreover, in both ST-2 and MC3T3
cells, siRNA-mediated reduction of CCN3 expression led to
an increase in ALP expression and enhanced activity of a
BMP reporter construct following BMP2 treatment. In
agreement with previous results, CCN3 was shown to bind
directly to BMP2. When investigating osteoclast differenti-
ation, calvarial cultures from CCN3
−/− mice displayed
higher numbers of osteoclasts when vitamin D3 was used
as an inducer of osteoclastogenesis, raising the possibility
that CCN3 suppresses osteoclast differentiation as well
(Canalis et al. 2010).
Together, thesedata support a roleforCCN3 asaninhibitor
of osteoblast differentiation through multiple mechanisms,
which include interfering with BMP2 and/or Wnt/β-Catenin
signaling or via activation of the Notch1 pathway (Fig. 2)
(Canalis 2007; Rydziel et al. 2007; Yamaguchi et al. 2008;
Smerdel-Ramoya et al. 2011). It should be noted that not all
studies are in agreement with a role for CCN3 in negatively
regulating osteoblast differentiation. In fact, a recent study
demonstrated that CCN3 favors osteoblast differentiation and
bone mineralization by inducing the expression of BMP-4, a
potent inducer of osteoblast differentiation. These CCN3-
mediated effects were dependent on α5β1a n dαvβ5
integrin receptors and subsequent activation of Integrin
Linked Kinase (ILK), p38 and c-Jun Kinase (JNK) (Tan
et al. 2011). Interestingly, the concentrations of CCN3 (3–
30 ng/ml) that induced osteoblast differentiation were much
lower when compared to CCN3 concentrations (300–
600 ng/mL) that blocked osteoblast differentiation (Rydziel
et al. 2007; Ouellet et al. 2011; Tan et al. 2011). These
observations are reminiscent of the in vivo data, which
revealed different effects depending on whether CCN3
was present in physiological levels or whether it was
overexpressed.
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Osteosarcoma Osteosarcoma is comprised of a group of
neoplasms that are usually of high grade and stage when
diagnosed. They are thought to originate from mesenchymal
cells having osteoblastic features. The incidence of this
cancer is low in the general population although it is the
most diagnosed and lethal bone cancer in young adults
(Tang et al. 2008). CCN3 expression in osteosarcoma cell
lines is variable. Immunohistochemistry performed on mus-
culoskeletal tumors reveal high CCN3 expression in osteo-
blasts, osteoclasts, chondrocytes and skeletal muscle cells.
Interestingly, primary tumors of osteosarcoma patients, who
developed lung metastases, presented with high CCN3 ex-
pression (Manara et al. 2002).
Using osteosarcoma derived cell lines; CCN3 expression
was found to be inversely correlated with ALP expression
(Manara et al. 2002). It is known that osteosarcomas are
characterized by impaired osteoblastic differentiation and
generally lack markers of terminal differentiation, which
has been associated with disrupted Runx2 function (Thomas
et al. 2004). Interestingly, forced expression of CCN3 in
normal osteoblasts can result in Notch pathway driven inhi-
bition of Runx2 (Minamizato et al. 2007). Moreover, CCN3
has been shown to be upregulated in osteoblast-like osteo-
sarcoma Saos-2 and OS7 cell lines (Perbal et al. 2008).
Thus, it has been hypothesized that high CCN3 expression
in osteosarcoma might activate Notch signaling, resulting in
osteosarcoma cells being locked into an early stage of oste-
oblastic differentiation. In agreement with this hypothesis,
CCN3 mRNA levels are increased in osteosarcoma cell lines
and tumor tissues when compared to osteoblasts. Indeed, high
CCN3 expression in osteosarcomas was not associated with
osteoblast differentiation markers and, more importantly, cor-
related with shorter disease free survival (Perbal et al. 2008).
This clinical correlation is in agreement with the recent obser-
vation that CCN3 can enhance the migratory properties of
osteosarcoma cells, which involves αvβ5 integrin-mediated
upregulation of COX-2 expression (Huang et al. 2011).
Ewing’s sarcoma Ewing’s sarcoma is the second most com-
monly diagnosed bone tumor and is found in rapidly grow-
ing bone of children (Jurgens and Dirksen 2011). While
CCN3 is expressed in approximately 30% of Ewing’s sar-
comas, it is associated with shorter disease free survival
(Manara et al. 2002). Ewing’s sarcoma cell line (TC71)
engineered to overexpress CCN3 displayed decreased cell
proliferation in vitro, growth in soft agar and tumorigenicity
when injected into mice (Benini et al. 2005). However, these
CCN3-expressing cells showed increased migration and
invasion using Boyden chamber assays. Increases in cell
invasion were correlated with increased levels of MMP9
associated with the cell surface (Benini et al. 2005).
MMP9 was previously shown to trigger the switch between
the stationary and migratory state by altering cytoskeleton
rearrangement through activation of RhoA/Paxillin/β-cate-
nin signaling (Sanceau et al. 2003). In addition, overexpres-
sion of CCN3 caused a decrease in cancer cell adhesion to
collagen I and collagen IV, which might be due to decreased
levels of α2β1 integrin. However, no significant differences
CCN3
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Differentiation
Osteoblast Differentiation
Osteoclasts
RANKL
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Cells
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Fig. 3 Potential roles for CCN3 in promoting the formation of osteo-
lytic breast cancer metastases. CCN3 expressed by breast cancer cells
can block the differentiation of mature osteoblasts, utilizing the mech-
anisms outlined in Fig. 2. This would result in a tip towards higher
levels of Receptor Activator of NF-κB Ligand (RANKL) produced by
pre-osteoblasts and less Osteoprotegerin (OPG). The higher levels of
RANKL would serve to induce the differentiation of monocytes into
osteoclasts. In concert with its negative effects on osteoblast differen-
tiation, CCN3 can also sensitize osteoclast precursors to respond to
RANKL, enhancing osteoclastogenesis and bone resorption
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to Laminin, Fibronectin or Vitronectin (Benini et al. 2005).
Immunohistochemistry on 170 human Ewing’s sarcoma
samples revealed that CCN3 was more highly expressed in
recurrences (6/8) and metastases (8/10) when compared to
the primary tumor (79/152). Microarray analyses on 30
Ewing’s tumors, coupled with immunohistochemistry on
125 cases that possessed sufficient clinical data and
follow-up, revealed that low levels of CCN3 expression
were associated with better patient prognosis when disease
free and overall survival was considered. Interestingly, do-
main specific antibodies revealed that 41% of the tumors
expressed a protein lacking the VWC domain. Expression of
this truncated protein confers a better prognosis to the pa-
tient (Perbal et al. 2009).
Chondrosarcoma Chondrosarcoma are malignant tumors of
cartilage tissue that do not respond well to chemotherapy or
radiotherapy treatment (Jamil et al. 2010). CCN3 expression
in chondrosarcoma was reported to be higher in well-
differentiated tumors and associated with a better patient
prognosis (Manara et al. 2002; Yu et al. 2003; Benini et al.
2005). Immunohistochemical analyses revealed that infil-
trates of giant-cells within chondrosarcomas exhibited
strong staining of CCN3 (Manara et al. 2002). Studies on
a chondrosarcoma-derived cell line showed that CCN3
increases their migration and up-regulates MMP-13 expres-
sion and activity. CCN3-induced migration was associated
with engagement of the αvβ5a n dαvβ3 integrins and
subsequent activation of Focal Adhesion Kinase, Phospha-
tidylinositol 3- kinase, Akt and NF-κB signaling pathways
(Tzeng et al. 2011).
These data reveal that CCN3 can play diverse roles in
modulating the malignant phenotype in primary bone can-
cers. In osteosarcoma, CCN3 enhances the malignant phe-
notype of these cancer cells by limiting the extent of
osteoblastic differentiation and promoting their migratory
and invasive properties. Similarly, high CCN3 expression
is also associated with a poor outcome in Ewing’s Sarcoma
and elicits enhanced migratory and invasive responses in
these cells. In contrast, CCN3 expression has been associ-
ated with a more differentiated phenotype and better prog-
nosis in chondrosarcoma. These differences likely reflect the
role played by CCN3 in the normal differentiation programs
of chondrocytes and osteoblasts. CCN3 is a positive regu-
lator of chondrocyte differentiation through the induction of
TGF-β2, which is important during the condensation stage
of chondrocyte differentiation (Kawai et al. 1999). More-
over, TGF-β1 functions to impair chondrocyte differentia-
tion (Valcourt et al. 2003), and has been shown to diminish
CCN3 levels (Parisi et al. 2006). In contrast, CCN3 acts as a
negative regulator of osteoblast differentiation. Thus, the
prognostic significance of CCN3 may be linked to its
normal role during the differentiation of these bone resident
cells.
CCN3 expression in bone metastatic cancers
The vast majority of cancers affecting bone are not derived
from primary bone tumors, but rather metastatic cancer cells
that have spread from distant organs to colonize the bone.
The two solid cancers that metastasize with the highest
frequency to bone include breast and prostate cancer. Given
the effects CCN3 has on the differentiation and function of
bone resident cells, it may not be surprising that CCN3 has
been implicated in the progression of these cancers as well.
Breast cancer Breast cancer is the most frequently diag-
nosed cancer in North American woman. Immunohisto-
chemical staining of CCN3 in normal breast tissue, CCN3
reveals intense staining in epithelial cells, with weaker
immune-positivity in the stroma and endothelium (Jiang et
al. 2004). Several reports have investigated the association
of CCN3 expression with clinical parameters of patients
with breast cancer. In one small study, CCN3 transcript
levels did not correlate with clinical parameters such as
age of the patient, hormone receptor and HER2 status,
grade, stage, lymph node involvement or tumor size. Only
a fraction (5/44) of samples displayed higher levels of
CCN3 in the tumor compared to normal breast tissue (Xie
et al. 2001). In a different cohort of 122 human breast
tumors and 32 normal breast tissues, lower CCN3 mRNA
and protein levels were observed in tumor tissues when
compared to normal samples. In addition, CCN3 expression
was significantly lower in tumors of high grade in those
patients diagnosed at advanced stage of the disease (Jiang et
al. 2004). These studies argue that high CCN3 expression in
breast cancers is associated with a better outcome.
In breast cancer-derived cell lines, low expression of CCN3
was also reported in the aggressive MDA-MB-231 human cell
line when compared to the less invasive MCF-7 line (Jiang et
al. 2004). Using MCF-7 cell line as a breast cancer model,
CCN3 was reported to be a direct target of estrogen. Indeed,
CCN3 expression was repressed in MCF-7 cells following
treatment with estrogen (17-β-estradiol) (Vendrell et al.
2004). Breast cancers that express the Estrogen Receptor
(ER) are classified as luminal breast cancers and stratify
patients for disease management using anti-estrogen therapies
such as tamoxifen (Girdler and Brotherick 2000). However, a
portion of patients with ER + disease are intrinsically resistant
to Tamoxifen and the majority of patients that initially respond
to anti-estrogentherapies will develop resistance. Interestingly,
CCN3 expression wasfound tobeelevated inasub-population
of MCF-7 cells (MVLN) that were selected for resistance to
tamoxifenorfulvestrant(Demirpenceetal.1993;Ghay adetal.
80 V. Ouellet, P.M. Siegel2009). Moreover, CCN3 was highly expressed in breast can-
cers from patients who had relapsed following tamoxifen
treatment versus tumors from those that did not. In addition,
CCN3 was one of five genes associated with shorter disease
free survival in ER + patients treated with Tamoxifen (Ghayad
et al. 2009).
As mentioned previously, the effects of CCN3 can be
context dependent. Thus it has been shown that overexpres-
sion of CCN3 in MDA-MB-231 breast cancer cells results in
reduced growth but has no effect on breast cancer cell adhe-
sion to Collagen I, Collagen IV, Fibronectin or Vitronectin.
Rather, CCN3 expression enhanced the ability of MDA-MB-
231 cells to form spheroids in 3-D culture through increased
intercellular adhesion. Interestingly, full length CCN3 was
unable to induce the migration of MDA-MB-231 cells,
whereas a CCN3 mutant lacking the CT domain was able to
induce a migratory phenotype. These observations highlight
the diversity of responses elicited by CCN3 in different cell
types, even between ER + and ER- subtypes of breast cancer
(Sin et al. 2009).
Relatively little is known about the role of CCN3 in
metastatic breast cancer. The first hint that CCN3 may play
a role in organ-specific metastasis came from the analysis of
gene expression profiles derived from 58 breast cancer
metastases. Interestingly, CCN3 was found to be highly
expressed in the majority of the bone (16 samples) metasta-
ses but was detected at very low levels in metastases derived
from lung (18 samples), brain (19 samples) and liver (5
samples) (Zhang et al. 2009).
In our own work, we also have shown that CCN3 is
expressed in bone metastasis samples from patients with
breast cancer and have identified CCN3 as a gene highly
expressed at the mRNA and protein levels in 4T1 murine
breast cancer cells selected for their ability to metastasize to
bone (Rose et al. 2007; Ouellet et al. 2011). We also dem-
onstrated that CCN3 enhanced the bone metastatic ability of
66cl4 cells, which are known only to metastasize to the
lungs, without altering their growth in the mammary fat
pad (Ouellet et al. 2011). Our interest in CCN3 as a factor
that could promote the formation of osteolytic bone metas-
tases stemmed from its demonstrated roles in regulating the
differentiation and activity of bone resident cells, as dis-
cussed above. During the formation of osteolytic lesions,
the balance between bone formation and resorption is tipped
in favor osteoclast differentiation and bone destruction. In
agreement with previous studies, CCN3 was able to impair
osteoblast differentiation from primary bone marrow cul-
tures, resulting in higher RANKL/OPG ratios which would
enhance osteoclastogenesis. Furthermore, we demonstrated
that CCN3 promotes osteoclast differentiation from
RANKL-primed monocyte precursors (RAW264.7) through
a mechanism involving calcium oscillations and NFATc1
nuclear translocation (Ouellet et al. 2011). Interestingly,
the ability of CCN3 to promote the formation of osteolytic
bone metastases may reflect the fact that breast cancer cells
colonizing the bone would contribute to significantly ele-
vated levels of CCN3, which would tip the balance towards
osteoclastogenesis (Fig. 3).
Recently, it has been argued that the expression level of
CCN3 alone may not be the most informative, but rather the
ratio of CCN3 versus CCN1 or CCN2 is more important.
High CCN1/CCN3 or CCN2/CCN3 mRNA ratios were
found to be associated with a highly metastatic phenotype
in breast cancer cells. In addition, high expression of CCN2
relative to low CCN3 levels was associated with enhanced
tumor formation, angiogenesis and the ability to form bone
metastases (Ohgawara et al. 2011). This is in contrast to our
findings in which we observed high CCN3 levels in the
context of low CCN1 and CCN2 expression in bone meta-
static breast cancer cells (Ouellet et al. 2011)a n da l s o
contrasts with the observation that human breast cancer
bone metastases that display high CCN3 mRNA expression
(Zhang et al. 2009). One potential explanation for these
differences stems from the fact that we analyzed expression
of CCN family members in breast cancer cells that had
formed bone metastases and were explanted back into cul-
ture (Ouellet et al. 2011); whereas, CCN1/CCN3 and
CCN2/CCN3 ratios in the MDA-MB-231 model were de-
termined in unselected parental breast cancer cells that had
not formed bone metastases (Ohgawara et al. 2011). The
possibility that CCN3 expression is selected for in bone
metastases is substantiated by the detection of CCN3 spe-
cifically in bone metastases (Zhang et al. 2009). Indeed, the
notion that, following cancer cell selection and isolation
from distinct metastatic sites, the expression of genes in
the selected populations can vary dramatically from the
starting cell population is now widely accepted (Kang et
al. 2003; Minn et al. 2005; Rose et al. 2007; Bos et al. 2009;
Tabaries et al. 2011). The data supporting a high CCN2/
CCN3 ratio in the bone metastases was based solely on
immunohistochemical staining (Ohgawara et al. 2011).
However, immunohistochemical staining in bone metas-
tases derived from MDA-MB-231 cells cannot be used
to make such quantitative arguments regarding the rela-
tive ratio of CCN2 to CCN3, given that these antibodies
will undoubtedly have very different affinities for their
respect targets (Ohgawara et al. 2011).
Prostate cancer Relatively little is known concerning the
role of CCN3 in prostate cancer progression and metastasis.
Only one study has examined CCN3 levels in prostate
cancer cell lines and tissues, which revealed that CCN3
expression was higher in prostate cancer-derived cell lines
compared to immortalized prostate epithelial cells (Maillard
et al. 2001). It is intriguing to note that the highest level of
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metastases when injected into mice (Angelucci et al.
2004). Furthermore, 19 of 20 prostate adenocarcinoma
samples stained positively for CCN3 expression by immu-
nohistochemistry. However, the sample size was too small
to make meaningful correlations between the intensity of
CCN3 staining and Gleason score (Maillard et al. 2001).
The established role of CCN3 as an inhibitor of osteoblast
differentiation (Canalis 2007; Minamizato et al. 2007;
Rydziel et al. 2007; Katsuki et al. 2008; Yamaguchi et al.
2008; Katsube et al. 2009a; Canalis et al. 2010; Ouellet et al.
2011), coupled with the recent observation that low CCN3
concentrations may enhance osteoblastogenesis, raises the
intriguing possibility that CCN3 could play a role in lytic
and/or blastic bone metastases formation depending on the
level of CCN3 expression. However, this will require further
functional validation to determine whether CCN3 plays a
functional role in prostate cancer growth and metastasis to
bone.
Conclusion
CCN3 exerts numerous effects on both normal and trans-
formed cells, and the cellular responses can be very different
depending on the various CCN3 isoforms and the cellular
context in which CCN3 is acting. Moreover, increasing data
suggests that the ultimate outcome of cellular differentiation
that is regulated by CCN3 may also depend on the level of
CCN3 expression. Available data points toward an impor-
tant role for CCN3 in the negative regulation of osteoblast
differentiation, which has clear consequences for normal
bone homeostasis and turnover. In addition, CCN3 has been
implicated as a poor prognostic marker in several primary
bone cancers, including osteosarcoma and Ewing’s sarcoma.
Given the ability of CCN3 to modulate the differentiation
status and activity of bone resident cells, it is interesting to
note that breast cancer cells that metastasize to bone and
induce bone destruction select for high levels of CCN3
expression. Future studies will be needed to focus on the
modular domains within CCN3 that are important for the
pro-bone metastatic activities of CCN3. Moreover, very
little is known regarding the role of CCN3 in prostate cancer
progression and subsequent metastasis to bone.
These areas represent fertile ground for future experimen-
tation. What is clear is that CCN3 can play complex roles in
modulating cancer phenotypes, such as metastasis, as it does
in the regulation of normal cellular behavior. However, there
is growing evidence that CCN3 can influence the progres-
sion of primary bone cancers and act as an important pro-
metastatic factor in numerous cancers, including metastatic
cancers affecting bone.
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